文献速递淋巴瘤白血病

里氏综合征患者的临床结局与预后因素:西班牙慢性淋巴细胞白血病研究组(GELLC)的真实世界研究

Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
PubMed 文献 · Br J Haematol · 2020-06-09

该真实世界研究纳入西班牙慢性淋巴细胞白血病研究组(GELLC)11个中心的128例里氏综合征(RS)患者,其中弥漫大B细胞淋巴瘤(DLBCL)型112例、霍奇金淋巴瘤(HL)型15例、浆母细胞淋巴瘤1例。DLBCL型RS中位总生存(OS)为5.9个月,HL型为30.8个月;血小板计数<100×10^9/L、既往CLL治疗(0 vs ≥1)及TP53异常在多因素分析中保持独立预后影响。无上述因素者中位OS为75.3个月,具有1个或2个及以上因素者分别为25.5个月和3个月。

要点

  • DLBCL型RS中位OS为5.9个月,HL型RS为30.8个月。
  • 血小板<100×10^9/L、既往CLL治疗及TP53异常为独立预后因素。
  • 无上述因素者中位OS为75.3个月,1个或≥2个因素者分别为25.5和3个月。

核心结论

  • RS患者总体OS较差,但部分患者可获得长期生存。
  • RS的治疗仍是未被满足的医疗需求,需要新的治疗方法。

研究设计与样本

  • 西班牙慢性淋巴细胞白血病研究组(GELLC)11个中心的真实世界研究,纳入128例RS患者,包括DLBCL型112例、HL型15例和浆母细胞淋巴瘤1例。

主要发现

  • DLBCL型RS中位OS为5.9个月,HL型RS中位OS为30.8个月。
  • DLBCL型RS中与OS相关的因素包括ECOG体能状态、血红蛋白水平、血小板计数、血清乳酸脱氢酶和β2微球蛋白水平、与RS同时存在的CLL克隆中TP53异常、既往治疗线数及CLL与RS之间的克隆关系。
  • 多因素分析中,血小板计数<100×10^9/L、既往CLL治疗(0 vs ≥1)及TP53异常保持独立预后影响。
  • 无上述任何因素的患者中位OS为75.3个月,具有1个或2个及以上因素的患者中位OS分别为25.5个月和3个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Richter syndrome (RS) is an uncommon evolution of chronic lymphocytic leukaemia (CLL) with a dismal prognosis. Clinical-biological features predicting outcome and best therapeutic approach for these patients remain to be established. In this study, 128 patients with RS, including 112 diffuse large B-cell lymphoma (DLBCL)-type RS, 15 Hodgkin lymphoma (HL)-type RS, and one plasmablastic lymphoma, were identified in 11 centres of the Spanish CLL Study Group (GELLC). The median overall survival (OS) was 5·9 months for DLBCL-type RS and 30·8 months for HL-type RS. Eastern Cooperative Oncology Group Performance Status, haemoglobin level, platelet count, serum lactate dehydrogenase and β2-microglobulin levels, tumour protein p53 (TP53) abnormalities in the CLL clone concomitant to RS, number of prior therapies, and clonal relationship between CLL and RS, were associated with OS in patients with DLBCL-type RS. A platelet count of <100 × 109 /l, prior CLL therapy (0 vs. ≥1), and presence of TP53 alterations maintained an independent prognostic impact in the multivariate analysis. Patients without any of these factors had a better clinical outcome, with a median OS of 75·3 months, while patients with one or two or more of these factors presented a median OS of 25·5 and 3 months, respectively. Although OS of patients with RS is generally poor, a proportion of patients achieved prolonged survival. Treatment of RS remains a medical need, and further therapeutic approaches with novel therapies are warranted.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Abrisqueta P, Delgado J, Alcoceba M, et al. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol. 2020. PMID: 32519351. doi:10.1111/bjh.16748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。